<DOC>
	<DOCNO>NCT02681991</DOCNO>
	<brief_summary>Renamezin Capsule ( oral adsorbent ) lower indoxyl sulfate level patient chronic renal failure . 120 patient chronic renal failure ( baseline serum creatinine:1.5-5.0mg/dl ) . Renamezin administer 6.0mg/day . The treatment period 2 month . The change serum indoxyl sulfate evaluate .</brief_summary>
	<brief_title>Phase Ⅳ Clinical Trial Evaluate Renamezin Patients With Chronic Renal Failure .</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>1. patient spontaneously write consent participate clinical trial 2. men woman age 19 3. predialysis patient chronic renal failure stage patient 3 month patient hold stable state serum creatinine 1.5mg/dl 5.0mg/dl 4. patient noticeable change 12weeks screening expect change need therapy therapy chronic renal failure ( medication dose relate , diet therapy ) 1. patient pass digestive tract disorder 2. patient uncontrolled constipation symptom 3. patient suffer digestive tract ulcer esophageal varix 4. patient untreated severe hypertension ( DBP ≥ 120mmHg ) 5. patient hospitalize angina pectoris , cardiovascular disease diagnose serious arrhythmia cerebrovascular disease within 6 month 6. patient hepatic impairment ( 2 time great upper limit normal level AST , ALT ) 7. subject dependency alcohol 8. patient current infection 9. pregnant woman , nurse mother 10 . Patients possibility pregnancy ( However , negative case register ) 11. patient participate another clinical trial addition current clinical trial 12 . Patient fit clinical trial participation legal mentally</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>